Clevidipine
As of the edition of 20 October 2026, Clevidipine is a small molecule: marketed, first approved in 2008 (US); acts on CACNA1C, CACNA1D and CACNA1F and 1 more; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2013
- Kind
- Small molecule
- Brand name
- Cleviprex
- First approved
- 1 August 2008 (US)
- Approvals on record
- 6 in 4 regions
- Holder of the most recent approval
- Chiesi; 4 holders in all
- Registered trials
- 26, 11 stopped early
- Disease areas
- Heart and blood vessels; Nervous system; Lungs and airways; Cancer; Infections; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
8 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product8 company-target rows are on route B because of Clevidipine.
See the 8 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 3 | 1 | 1 | 1 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 4 | 1 | 0 | 3 |
| Phase 3 | 9 | 8 | 0 | 1 |
| Phase 4 | 9 | 2 | 1 | 6 |
| All trials | 26 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Novartis | Originator and Lead sponsor of trials | 2003 to now |
| Chiesi Farmaceutici | Applicant and Lead sponsor of trials | 2011 to now |
| Chiesi | Acquired holder | 2016 to now |